Eneapharm
- Company typePrivate
- Founded2018
- HeadquartersLabège, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Eneapharm firmographics
Firmographics- Name
- Eneapharm
- Legal name
- ENEAPHARM SAS
- Website
- https://eneapharm.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where Eneapharm is headquartered
LocationHeadquarters
- HQ city
- Labège
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Eneapharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, Eneapharm's primary revenue model will be derived from the sale of prescription pharmaceutical products upon regulatory approval. The company is developing a pipeline of therapeutic candidates for exocrine pancreatic insufficiency (EN311, EN3102, EN3103, EN3104) targeting both adult and pediatric populations.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Eneapharm product offering
Product offeringCore offering
Eneapharm is a clinical-stage biopharmaceutical company developing oral enzyme formulations for the treatment of exocrine pancreatic insufficiency (EPI). Its proprietary drug delivery technology enables targeted enzymatic release in the duodenum, and the pipeline comprises four candidates — EN311, EN3102, EN3103, and EN3104 — addressing adult, pediatric, and nasogastric patient populations.
Product overview
Eneapharm is a biopharmaceutical company developing innovative treatments for exocrine pancreatic insufficiency (EPI). The company's core portfolio includes four product candidates (EN311, EN3102, EN3103, EN3104) using a breakthrough formulation technology that enables targeted enzymatic release in the duodenum, overcoming limitations of current treatments. EN311 is the lead adult oral formulation, EN3102 targets pediatric patients, EN3103 is a first-in-class nasogastric form, and EN3104 focuses on bioavailability improvement. Products are available in multiple formulations including capsules, sticks, orodispersible tablets for adults and syrups for pediatric patients.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Approximately 70% of current treatments are inadequate due to slow enzyme release
- +2 more outcomes
Companies that use Eneapharm
Customer profileSegments5 records
Ideal customer profiles2 records
Eneapharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Eneapharm partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- SkyepharmacoreGMP Clinical Manufacturing Partnership for EN311. Skyepharma, a fully integrated CDMO (Contract Development and Manufacturing Organization), provides expertise in clinical batch manufacturing for EN311. This collaboration supports Eneapharm's commitment to optimizing development processes, enhancing operational excellence, and delivering high-quality pharmaceutical products. David Lescuyer and Benoit Mougeot from Skyepharma played key roles in establishing the partnership.
- NubbominorNubbo is a leading incubator supporting high-impact technological and societal innovations. Eneapharm joined the Nubbo incubation program to accelerate development, benefit from top-tier strategic support, and strengthen position within a vibrant innovation ecosystem.
- INSA (Institut National des Sciences Appliquées)coreInstitutional laboratory partner. Research collaboration through CIFRE contracts for doctoral research. Alexis Bages conducted research via a CIFRE contract funded by Eneapharm in connection with INSA, resulting in scientific publications in the European Journal of Pharmaceutics and Biopharmaceutics.
- CrittcoreInstitutional laboratory partner. Critt (Centre de Ressources en Innovation et Technologie) provides research and technology development support for Eneapharm's formulation technology.
- CHU ToulousecoreInstitutional partner. CHU Toulouse (Centre Hospitalier Universitaire) provides clinical research collaboration and healthcare expertise supporting Eneapharm's clinical development programs.
- SicovalminorLocal development agency for the Toulouse metropolitan area. Provides support for technology companies in the Sicoval region where Labège is located.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Eneapharm competitors and assessment
Company assessmentOthers
- Skyepharma: Fully integrated CDMO and Eneapharm's GMP clinical manufacturing partner for EN311. Highly relevant as an ecosystem participant enabling Eneapharm's clinical supply chain.
Direct peers
- Chiesi Farmaceutici: European pharmaceutical company with PERT and rare disease franchises including Pertyze; competes with Eneapharm in the EPI enzyme replacement market, particularly across EU geographies.
- AbbVie: Markets Creon, the leading pancreatic enzyme replacement therapy (PERT) and the dominant incumbent in the EPI space. Directly competes with Eneapharm's EN311 in the same patient population and prescriber base.
- Digestive Care (Pertzye): Markets Pertzye, a PERT product now under Perrigo, targeting similar cystic fibrosis and chronic pancreatitis EPI populations as Eneapharm's EN311 and EN3102.
- Nestle Health Science: Markets Zenpep and Viokace, established PERT products competing directly with Eneapharm's pipeline for the same EPI indications and physician specialty channels.
- Viatris: Sells generic and authorised generic PERT products globally. Competes with Eneapharm on price and formulary access in the same EPI prescriber and payer channels.
Broad incumbents
- Takeda Pharmaceutical: Global rare disease and GI pharma major following the Shire acquisition. Shire's former commercial leadership on Eneapharm's board reinforces the relevance of Takeda/Shire as a comparable strategic acquirer and broad PERT/rare disease incumbent.
- Ferring Pharmaceuticals: Specialty pharma with a strong gastroenterology and reproductive health portfolio, including prior PERT-related work. Eneapharm's QC/QA Director Pascal Bour previously held roles at Ferring, evidencing deep familiarity with the franchise.
Emerging players
- Alnylam Pharmaceuticals: Clinical-stage rare disease biopharmaceutical company with a similar go-to-market model of scientific publication, conference presence, and pharma partnership. Comparable in stage and disease-area specialisation, though in different therapeutic categories.
- Advicenne Pharma: Specialty pharma focused on rare nephrology and orphan indications, with comparable European clinical-stage profile. Eneapharm board member Ludovic Robin previously served as CBSO at Advicenne, evidencing operational and strategic parallels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Eneapharm social profiles
Digital presenceEneapharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eneapharm leadership team
Management profileNumber of profiles
Profiles7 records
Eneapharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eneapharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eneapharm
What does Eneapharm do?
Eneapharm is a clinical-stage biopharmaceutical company developing oral enzyme formulations for the treatment of exocrine pancreatic insufficiency (EPI). Its proprietary drug delivery technology enables targeted enzymatic release in the duodenum, and the pipeline comprises four candidates — EN311, EN3102, EN3103, and EN3104 — addressing adult, pediatric, and nasogastric patient populations.
Is Eneapharm a public or private company?
Eneapharm is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eneapharm founded?
Eneapharm was founded in 2018. It employs 1 to 10 people.
Where is Eneapharm based?
Eneapharm is headquartered in Labège, France, in the Europe region.
How does Eneapharm make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Eneapharm's main competitors?
Skyepharma is listed as an others. Direct peers are Chiesi Farmaceutici, AbbVie, Digestive Care (Pertzye), Nestle Health Science and Viatris. Broad incumbents are Takeda Pharmaceutical and Ferring Pharmaceuticals. Emerging players are Alnylam Pharmaceuticals and Advicenne Pharma.
Does Eneapharm have an API?
No public API is recorded for Eneapharm.